The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
Sodium glucose cotransporter 2 inhibitors (SGLT2) have been increasingly pursued as a promising target for addressing residual cardiovascular risk. Prior trials demonstrated that SGLT2i not only promotes glucose-lowering, but also improves endothelial dysfunction, adiposity, fluid overload, and insu...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2023-09-01
|
| coleção: | Frontiers in Clinical Diabetes and Healthcare |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fcdhc.2023.1243530/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|